Hepatotoxicity associated with lapatinib in an experimental rat model.

[1]  P. Goss,et al.  Hepatobiliary abnormalities in patients with metastatic cancer treated with lapatinib. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  K. King,et al.  HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  T. Wakamatsu,et al.  Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies , 2009, British Journal of Cancer.

[4]  T. Gruenberger,et al.  Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[5]  J. Ross,et al.  The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. , 2009, The oncologist.

[6]  Susan Goodin,et al.  Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. , 2008, Clinical Therapeutics.

[7]  J. Buckels,et al.  Effect of preoperative chemotherapy on liver resection for colorectal liver metastases. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[8]  Charles E. Geyer,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer , 2008 .

[9]  Kelly A. Harmon,et al.  The Role of Efflux and Uptake Transporters in N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, Lapatinib) Disposition and Drug Interactions , 2008, Drug Metabolism and Disposition.

[10]  J. Soria,et al.  Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy , 2008, Nature Clinical Practice Oncology.

[11]  T. Ruers,et al.  Hepatic veno-occlusive disease after neoadjuvant treatment of colorectal liver metastases with oxaliplatin: a lesson of the month. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[12]  P. Bachellier,et al.  Sinusoidal Injury Increases Morbidity After Major Hepatectomy in Patients With Colorectal Liver Metastases Receiving Preoperative Chemotherapy , 2008, Annals of surgery.

[13]  L. Ellis,et al.  Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin‐based chemotherapy for colorectal liver metastases , 2007, Cancer.

[14]  R. D. Connell,et al.  Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor. , 2007, Cancer research.

[15]  C. Bennett,et al.  Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. , 2007, Leukemia research.

[16]  T. Pawlik,et al.  Chemotherapy‐associated hepatotoxicity and surgery for colorectal liver metastases , 2007, The British journal of surgery.

[17]  M. Piccart,et al.  Progress and new standards of care in the management of HER-2 positive breast cancer. , 2007, European journal of cancer.

[18]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[19]  Daniel Azoulay,et al.  Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  B. Nordlinger,et al.  Benefits and risks of neoadjuvant therapy for liver metastases. , 2006, Journal of Clinical Oncology.

[21]  A. Citri,et al.  EGF–ERBB signalling: towards the systems level , 2006, Nature Reviews Molecular Cell Biology.

[22]  A. Pariente,et al.  Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour. , 2006, European journal of gastroenterology & hepatology.

[23]  Jorma Isola,et al.  Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. , 2006, The New England journal of medicine.

[24]  Cheryl Ho,et al.  Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[26]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[27]  Suzanne F. Jones,et al.  Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Mariël Brok,et al.  Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps , 2005, Cancer biology & therapy.

[29]  N. Lin,et al.  Fatal hepatic necrosis following imatinib mesylate therapy. , 2003, Blood.

[30]  T. Thalhammer,et al.  Biliary excretion of flavopiridol and its glucuronides in the isolated perfused rat liver: role of multidrug resistance protein 2 (Mrp2). , 2003, Life sciences.

[31]  M. Piccart,et al.  Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  T. Tauchi,et al.  Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis , 2002, Leukemia.

[33]  G. McDonald,et al.  Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. , 2002, Blood.

[34]  M. Baccarani,et al.  Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. , 2002, Blood.

[35]  K. Lackey,et al.  The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. , 2001, Molecular cancer therapeutics.

[36]  M. Birnbaum,et al.  Akt/Protein Kinase B Isoforms Are Differentially Regulated by Epidermal Growth Factor Stimulation* , 2000, The Journal of Biological Chemistry.

[37]  D. Stern.  Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases , 2000, Breast Cancer Research.

[38]  D. Stern,et al.  Specificity within the EGF family/ErbB receptor family signaling network , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.

[39]  J G Klijn,et al.  The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. , 1992, Endocrine reviews.